Explore more publications!
Idaho Healthcare Hub
Submit Press Release

Idaho Healthcare Hub: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Idaho Healthcare Hub.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 29, 2025

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
September 29, 2025

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Indeterminate GlobeNewswire
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine
September 29, 2025

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

Indeterminate GlobeNewswire
Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation
September 29, 2025

Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation

Indeterminate GlobeNewswire
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
September 29, 2025

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Indeterminate GlobeNewswire
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
September 29, 2025

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

Indeterminate GlobeNewswire
Neura Health Secures $11.4 Million Series A to Fuel National Expansion of Comprehensive, Tech-Enabled Neurology Care Model
September 29, 2025

Neura Health Secures $11.4 Million Series A to Fuel National Expansion of Comprehensive, Tech-Enabled Neurology Care Model

Indeterminate GlobeNewswire
Apyx Medical to Host Virtual Key Opinion Leader Event to Discuss the Commercial Launch of The AYON Body Contouring System™ on October 14, 2025
September 29, 2025

Apyx Medical to Host Virtual Key Opinion Leader Event to Discuss the Commercial Launch of The AYON Body Contouring System™ on October 14, 2025

Indeterminate GlobeNewswire
The Oncology Institute Partners with Protocol Behavioral Health to Integrate Mental Health Services into Cancer Care
September 29, 2025

The Oncology Institute Partners with Protocol Behavioral Health to Integrate Mental Health Services into Cancer Care

Indeterminate GlobeNewswire
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
September 29, 2025

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Indeterminate GlobeNewswire
electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium
September 29, 2025

electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium

Indeterminate GlobeNewswire
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
September 29, 2025

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Indeterminate GlobeNewswire
Reflect Scientific Secures Over $1 Million in Follow-On Orders for B-90 Blast Freezer
September 29, 2025

Reflect Scientific Secures Over $1 Million in Follow-On Orders for B-90 Blast Freezer

Indeterminate GlobeNewswire
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
September 29, 2025

Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston

Indeterminate GlobeNewswire
Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer
September 29, 2025

Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

Indeterminate GlobeNewswire
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
September 29, 2025

Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer

Indeterminate GlobeNewswire
MindRank Announces Positive 12-week Once-Daily (QD) Results for AI-Designed Oral GLP-1 Agonist MDR-001 in Adults with Obesity
September 29, 2025

MindRank Announces Positive 12-week Once-Daily (QD) Results for AI-Designed Oral GLP-1 Agonist MDR-001 in Adults with Obesity

Indeterminate GlobeNewswire
Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment
September 29, 2025

Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment

Indeterminate GlobeNewswire
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
September 29, 2025

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal

Indeterminate GlobeNewswire
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
September 29, 2025

KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

Indeterminate GlobeNewswire
Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025
September 29, 2025

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions